DEA Bans Doc Elhorr from Pill Dispenser Club—Details Inside
Published Date: 10/20/2025
Notice
Summary
Dr. Ali Elhorr faced a formal decision that affects his professional status, with important consequences for his medical practice and reputation. This order sets clear rules and timelines he must follow, impacting his career and possibly his income. Anyone involved in medical licensing or healthcare oversight should pay attention to these changes.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 1 costs, 1 mixed.
Order Limits Dr. Ali Elhorr's Practice
This Decision and Order affects Dr. Ali Elhorr's professional status and sets rules and timelines he must follow. Those rules may limit his medical practice, affect his reputation, and could have consequences for his career and possibly his income.
Licensing Boards Should Monitor Order
The order is relevant to people and organizations involved in medical licensing and healthcare oversight. Licensing boards, regulators, and similar oversight bodies should pay attention to the rules and timelines set in this Decision and Order.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
Previous / Next Documents
Previous: 2025-19598 — Abolghasem Rezaei, M.D.; Decision and Order
Dr. Abolghasem Rezaei from Oklahoma lost his DEA registration because he no longer has the state permission to handle controlled substances. Since he didn’t ask for a hearing, the DEA canceled his registration by default, meaning he can’t legally prescribe or manage these drugs anymore. This change is effective immediately and impacts Dr. Rezaei’s ability to work with controlled substances.
Next: 2025-19600 — Chantal F. Nouvellon, D.O.; Decision and Order
Dr. Chantal F. Nouvellon’s case decision affects healthcare providers by clarifying important rules about her professional status. This decision sets clear expectations and may impact how similar cases are handled in the future. No immediate money changes, but it’s a big deal for anyone involved in related medical licensing matters.